Teva and alvotech announce simlandi® (adalimumab-ryvk) injection now available in the u.s.

Reykjavik, iceland & parsippany, nj  — teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva) and alvotech (nasdaq: alvo), today announced the availability of simlandi (adalimumab-ryvk) injection in the u.s., as an interchangeable biosimilar to humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, crohn's disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis.
ALVO Ratings Summary
ALVO Quant Ranking